Clinical Trials · NCT00378690
A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Astellas Pharma Inc
- Enrollment
- 706
- Start date
- Mar 2006
- Locations
- 71 sites, 10 countries
- Primary endpoint
- Time to PSA progression